• Verastem appointed Michael P. Bailey to its board.
• Bailey is CEO of AVEO Pharmaceuticals, an LG Chem company, where he led its 2023 acquisition by LG Chem.
• He previously held senior commercial roles at Synta Pharmaceuticals, ImClone Systems, Genentech, and SmithKline Beecham.
• Board member Robert Gagnon stepped down following the end of his term on May 21, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260526488039) on May 26, 2026, and is solely responsible for the information contained therein.